Auspex Pharmaceuticals Raises $25M For Phase 3 Trials

San Diego-based Auspex Pharmaceuticals announced this morning that it has raised $25M in a funding round, a Series D financing for the company. The round was led by Panorama Capital, and also included Thomas, McNerney & Partners, CMEA Capital, and Sloan Biotech Fund. The firm said the funding will go towards a Phase 3 clinical trail of its lead compound. The firm is working on a treatment for movement disorder (Chorea) due to Huntington's Disease, Tourette syndrome and tardive dyskinesia. More information »